Donna L Berry1, Fangxin Hong2, Traci M Blonquist2, Barbara Halpenny2, Christopher P Filson3, Viraj A Master3, Martin G Sanda3, Peter Chang4, Gary W Chien5, Randy A Jones6, Tracey L Krupski7, Seth Wolpin8, Leslie Wilson9, Julia H Hayes2, Quoc-Dien Trinh10, Mitchell Sokoloff11, Prabhakara Somayaji12. 1. Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Boston, Massachusetts. Electronic address: donna_berry@dfci.harvard.edu. 2. Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Boston, Massachusetts. 3. Department of Urology, Emory University School of Medicine, Atlanta, Georgia. 4. Department of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 5. Department of Urology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California. 6. University of Virginia Schools of Nursing, Charlottesville, Virginia. 7. Department of Urology, School of Medicine, Charlottesville, Virginia. 8. University of Washington School of Nursing, Seattle, Washington. 9. Department of Clinical Pharmacy, University of California-San Francisco, San Francisco, California. 10. Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts. 11. Department of Urology, University of Massachusetts Memorial Healthcare, Worcester, Massachusetts. 12. Private Practice, Niagara Falls, New York.
Abstract
PURPOSE: We evaluated the efficacy of the web based P3P (Personal Patient Profile-Prostate) decision aid vs usual care with regard to decisional conflict in men with localized prostate cancer. MATERIALS AND METHODS: A randomized (1:1), controlled, parallel group, nonblinded trial was performed in 4 regions of the United States. Eligible men had clinically localized prostate cancer and an upcoming consultation, and they spoke and read English or Spanish. Participants answered questionnaires to report decision making stage, personal characteristics, concerns and preferences plus baseline symptoms and decisional conflict. A randomization algorithm allocated participants to receive tailored education and communication coaching, generic teaching sheets and external websites plus a 1-page summary to clinicians (intervention) or the links plus materials provided in clinic (usual care). Conflict outcomes and the number of consultations were measured at 1 month. Univariate and multivariable models were used to analyze outcomes. RESULTS:A total of 392 men were randomized, including 198 to intervention and 194 to usual care, of whom 152 and 153, respectively, returned 1-month outcomes. The mean ± SD 1-month decisional conflict scale (score range 0 to 100) was 10.9 ± 16.7 for intervention and 9.9 ± 18.0 for usual care. The multivariable model revealed significantly reduced conflict in the intervention group (-5.00, 95% CI -9.40--0.59). Other predictors of conflict included income, marital or partner status, decision status, number of consultations, clinical site and D'Amico risk classification. CONCLUSIONS: In this multicenter trial the decision aid significantly reduced decisional conflict. Other variables impacted conflict and modified the effect of the decision aid, notably risk classification, consultations and resources. P3P is an effective adjunct for shared decision making in men with localized prostate cancer.
RCT Entities:
PURPOSE: We evaluated the efficacy of the web based P3P (Personal Patient Profile-Prostate) decision aid vs usual care with regard to decisional conflict in men with localized prostate cancer. MATERIALS AND METHODS: A randomized (1:1), controlled, parallel group, nonblinded trial was performed in 4 regions of the United States. Eligible men had clinically localized prostate cancer and an upcoming consultation, and they spoke and read English or Spanish. Participants answered questionnaires to report decision making stage, personal characteristics, concerns and preferences plus baseline symptoms and decisional conflict. A randomization algorithm allocated participants to receive tailored education and communication coaching, generic teaching sheets and external websites plus a 1-page summary to clinicians (intervention) or the links plus materials provided in clinic (usual care). Conflict outcomes and the number of consultations were measured at 1 month. Univariate and multivariable models were used to analyze outcomes. RESULTS: A total of 392 men were randomized, including 198 to intervention and 194 to usual care, of whom 152 and 153, respectively, returned 1-month outcomes. The mean ± SD 1-month decisional conflict scale (score range 0 to 100) was 10.9 ± 16.7 for intervention and 9.9 ± 18.0 for usual care. The multivariable model revealed significantly reduced conflict in the intervention group (-5.00, 95% CI -9.40--0.59). Other predictors of conflict included income, marital or partner status, decision status, number of consultations, clinical site and D'Amico risk classification. CONCLUSIONS: In this multicenter trial the decision aid significantly reduced decisional conflict. Other variables impacted conflict and modified the effect of the decision aid, notably risk classification, consultations and resources. P3P is an effective adjunct for shared decision making in men with localized prostate cancer.
Authors: Deb Feldman-Stewart; Christine Tong; Rob Siemens; Shabbir Alibhai; Tom Pickles; John Robinson; Michael D Brundage Journal: Med Decis Making Date: 2012-01-27 Impact factor: 2.583
Authors: Suzanne K Linder; Paul R Swank; Sally W Vernon; Patricia D Mullen; Robert O Morgan; Robert J Volk Journal: Patient Educ Couns Date: 2011-02-05
Authors: David C Johnson; Dana E Mueller; Allison M Deal; Mary W Dunn; Angela B Smith; Michael E Woods; Eric M Wallen; Raj S Pruthi; Matthew E Nielsen Journal: J Urol Date: 2016-06-23 Impact factor: 7.450
Authors: Merle H Mishel; Barbara B Germino; Lin Lin; Raj S Pruthi; Eric M Wallen; Jaime Crandell; Diane Blyler Journal: Patient Educ Couns Date: 2009-10-09
Authors: Donna L Berry; Barbara Halpenny; Seth Wolpin; B Joyce Davison; William J Ellis; William B Lober; Justin McReynolds; Jennifer Wulff Journal: J Med Internet Res Date: 2010-12-17 Impact factor: 5.428
Authors: David D Thiel; Andrew J Davidiuk; Gregory A Broderick; Michelle Arnold; Nancy Diehl; Andrea Tavlarides; Kaitlynn Custer; Alexander S Parker Journal: BMC Urol Date: 2015-07-01 Impact factor: 2.264
Authors: Giulia I Lane; Ajith Dupati; Ji Qi; Stephanie Ferrante; Rodney L Dunn; Roshan Paudel; Daniela Wittmann; Lauren Wallner; Donna L Berry; Chad Ellimoottil; James Montie; J Quentin Clemens Journal: Urol Pract Date: 2022-01-01
Authors: Giulia I Lane; Ji Qi; Ajith Dupati; Stephanie Ferrante; Rodney L Dunn; Roshan Paudel; Daniela Wittmann; Lauren P Wallner; Donna L Berry; Chad Ellimoottil; James E Montie; J Quentin Clemens Journal: Urology Date: 2022-02-24 Impact factor: 2.633
Authors: Janet Jull; Sascha Köpke; Maureen Smith; Meg Carley; Jeanette Finderup; Anne C Rahn; Laura Boland; Sandra Dunn; Andrew A Dwyer; Jürgen Kasper; Simone Maria Kienlin; France Légaré; Krystina B Lewis; Anne Lyddiatt; Claudia Rutherford; Junqiang Zhao; Tamara Rader; Ian D Graham; Dawn Stacey Journal: Cochrane Database Syst Rev Date: 2021-11-08
Authors: Christopher P Filson; Fangxin Hong; Niya Xiong; Rachel Pozzar; Barbara Halpenny; Donna L Berry Journal: Cancer Date: 2021-02-05 Impact factor: 6.921
Authors: Donna L Berry; Fangxin Hong; Traci M Blonquist; Barbara Halpenny; Niya Xiong; Christopher P Filson; Viraj A Master; Martin G Sanda; Peter Chang; Gary W Chien; Randy A Jones; Tracey L Krupski; Seth Wolpin; Leslie Wilson; Julia H Hayes; Quoc-Dien Trinh; Mitchell Sokoloff Journal: Urol Oncol Date: 2021-01-19 Impact factor: 2.954
Authors: Donna L Berry; Fangxin Hong; Barbara Halpenny; Martin G Sanda; Viraj A Master; Christopher P Filson; Peter Chang; Gary W Chien; Meghan Underhill; Erica Fox; Justin McReynolds; Seth Wolpin Journal: Urol Pract Date: 2018-03-20
Authors: Joaquin Michel; Jorge Ballon; Sarah E Connor; David C Johnson; Jonathan Bergman; Christopher S Saigal; Mark S Litwin; Dana L Alden Journal: MDM Policy Pract Date: 2021-05-27
Authors: Roshan Paudel; Stephanie Ferrante; Ji Qi; Rodney L Dunn; Donna L Berry; Alice Semerjian; Christopher M Brede; Arvin K George; Brian R Lane; Kevin B Ginsburg; James E Montie; Giulia I Lane Journal: Urology Date: 2021-04-29 Impact factor: 2.633